Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

JOHNSON & JOHNSON : DePuy Orthopaedics Receives FDA 510(K) Clearance for TRUMATCH ® Personalized Solutions for TRUMATCH® Personalized Solutions

share with twitter share with LinkedIn share with facebook
08/19/2011 | 03:10pm EDT
Brings New Level of Personalization and Efficiency to Total Knee Replacement Surgery Through Customized Instrumentation

WARSAW, IN – Aug. 19, 2011 – DePuy Orthopaedics, Inc. (DePuy) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of TRUMATCH® Personalized Solutions with the company's SIGMA® Fixed-Bearing Knee System, one of the most widely used knee systems in the world.

TRUMATCH Personalized Solutions, which the company announced is available immediately, is a surgical instrumentation and computer software system that is designed to aid in knee implant positioning and procedure efficiency. TRUMATCH Solutions helps reduce costs by decreasing OR time by an average of 35 minutes.1 Procedures require less instrumentation and eliminate up to nine surgical steps compared to total knee replacement performed without TRUMATCH Solutions.

"TRUMATCH technology helps surgeons consistently provide knee replacement patients a customized fit and enables them to do the operation in less time," said Daniel P. Hoeffel, MD, of Summit Orthopaedic Group, St. Paul, Minnesota.* "Patients, surgeons and the health care system all benefit from advancements in technology that provide greater efficiencies and individualize treatment."

TRUMATCH Solutions is the first system to utilize CT scans and computer software to guide the development and production of femoral and tibial cutting blocks that are individually prepared to match the actual bone surfaces of each patient. Precise positioning of the knee implant is critical to its overall performance.2 Also, the use of CT scans, rather than MRIs, results in improved bone imaging, less scanning time and lower costs.3

"TRUMATCH Personalized Solutions, only available from DePuy, represents a meaningful advance for knee replacement patients," said Andrew Ekdahl, President, DePuy Orthopaedics. "This proprietary system is a win for patients, surgeons and hospitals that has the potential to improve patient care while reducing costs -- a very important combination in health care today." The FDA clearance of TRUMATCH Solutions was based in part on mechanical and alignment accuracy testing. TRUMATCH Solutions is available in 12 other countries.

SIGMA® Knee System

The SIGMA® Knee System has been provided for nearly 1 million patients.4 In fact, one study has shown that 10 years after surgery, 99.6 percent of patients still depend on SIGMA Knees with the fixed-bearing option in their daily lives.5 In another study of people five to ten years after surgery with Fixed-Bearing SIGMA Knee implants, most reported that the surgery had resulted in excellent relief of pain, improved range of motion and better function of the knee.6 Fixed-bearing knees are the most widely used knee replacements in the United States today. The SIGMA Knee with fixed-bearing option is a leader in this type of knee system. SIGMA Fixed- Bearing Knees are based on the clinically proven P.F.C.® Knee.7 DePuy Orthopaedics knee replacements have over 30 years of clinical experience.8

Important Safety Information

The performance of knee replacements depends on age, weight, activity level, and other factors. There are potential risks and recovery takes time. People with conditions limiting rehabilitation should not have this surgery. Only an orthopaedic surgeon can determine if knee replacement is indicated based on an individual patient's condition.

About DePuy Orthopaedics

DePuy Orthopaedics, Inc., a Johnson & Johnson company, is a leading global provider of orthopaedic devices for hip, knee, and trauma and extremities as well as bone cement and operating room products. It is part of the DePuy Family of Companies, which has a rich heritage of pioneering a broad range of products and solutions across the continuum of orthopaedic and neurological care. These companies are unified under one vision – Never Stop Moving® – to express their commitment to bring meaningful innovation, shared knowledge and quality care to patients throughout the world. Visit www.depuy.com for more information.

###

*Dr. Daniel P. Hoeffel is a consultant to DePuy Orthopaedics.

1 Data on file at DePuy. Operating room time includes preparation, operating room, and turnover time.

2 Werner, F. et al. "The effect of valgus/varus malalignment on load distribution in total knee replacements." Journal of Biomechanics. 2005;38:349-355.; Cates, H. et al. "Intramedullary Versus Extramedullary Femoral Alignment Systems in Total Knee Replacement." Clinical Orthopaedics and Related Research. 1993;286:32-39;3. Ritter, M. et al. "Postoperative Alignment of Total Knee Replacement," Clinical Orthopaedics and Related Research. 1994; 299:153-156; Sorrells, B. et al. "The effect of varus and valgus deformity on results of cementless mobile bearing TKA." The Knee. 2007;14:284-288.

3 D. White, K. L. Chelule, B. B. Seedhom. Accuracy of MRI vs CT imaging with particular reference to patient

specific templates for total knee replacement surgery. Int J Med Robotics Comput Assist Surg 2008; 4: 224–231. "Thus, in light of the limitations of MRI noted above, in addition to the high costs, CT is likely to provide the optimum surgical outcome when used to manufacture our patient-specific templates."

4 Data on file at DePuy.

5 Dalury, et al. Midterm results with the P.F.C. SIGMA Total Knee Arthroplasty System. The Journal of Arthroplasty. Vol. 23. No. 2, 2008: 175-181.

6 Buechel Sr., F. F., Buechel Jr., F. F., Pappas M. J., D'Alessio J. Twenty-year evaluation of meniscal bearing and rotating platform knee replacements. Clinical Orthopaedics and Related Research. 2001; 388:41-50.

7 Dixon M., et al. "Modular Fixed-Bearing Total Knee Arthroplasty with Retention of the Posterior Cruciate Ligament. A Study of Patients Followed for a Minimum of Fifteen Years.

Surgery. 2005; 87:598-603.

8 Buechel, Sr., F. F., F. F. Buechel, Jr., M. J. Pappas and M.S. D'Alessio. "Twenty Year Evaluation of Meniscal Bearing and Rotating Platform Knee Replacements." Clinical Orthopaedics and Related Research. Vol. 388, July 2001: 41-50.

share with twitter share with LinkedIn share with facebook
All news about JOHNSON & JOHNSON
02:22pJ&J kicks off final study of single-shot COVID-19 vaccine in 60,000 volunteer..
RE
02:18pJ&J kicks off final study of single-shot COVID-19 vaccine in 60,000 volunteer..
RE
12:00pJohnson & Johnson Begins Final-Stage Testing of Covid-19 Vaccine
DJ
11:50aJOHNSON & JOHNSON : Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's..
PU
11:48aJOHNSON & JOHNSON : Late-stage study of first single-shot vaccine begins in US
AQ
11:46aJOHNSON & JOHNSON : Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's..
AQ
09/22JOHNSON & JOHNSON : - BAND-AID Brand Delivers Modern Day 'CARE Packages' to Fron..
AQ
09/22JOHNSON & JOHNSON : BAND-AID Brand Delivers Modern Day 'CARE Packages' to Frontl..
AQ
09/21JOHNSON & JOHNSON : BAND-AID® Brand Delivers Modern Day “CARE Packages&rdq..
PU
09/21JOHNSON & JOHNSON : Janssen Presents Findings from Global, Multi-Center Trial Ex..
AQ
More news
Financials (USD)
Sales 2020 80 541 M - -
Net income 2020 16 242 M - -
Net Debt 2020 3 827 M - -
P/E ratio 2020 23,7x
Yield 2020 2,78%
Capitalization 380 B 380 B -
EV / Sales 2020 4,76x
EV / Sales 2021 4,26x
Nbr of Employees 132 200
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 162,89 $
Last Close Price 144,21 $
Spread / Highest target 24,8%
Spread / Average Target 13,0%
Spread / Lowest Target -2,23%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.14%379 679
ROCHE HOLDING AG8.39%315 948
MERCK & CO., INC.-8.81%209 775
PFIZER, INC.-8.07%201 437
NOVARTIS AG-11.13%195 696
NOVO NORDISK A/S13.07%160 063